undamentalytics Newsletter
Sign in

Eyepoint, Inc. income statement

In fiscal 2025, Eyepoint, Inc. reported revenue of $31.4m, down 27.5% on the year before, operating income of −$243m (a -776.0% margin) and net income of −$232m, or −$3.17 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue23542327283203437414643313
Research and development777710121415161517295065133221263
Selling and marketing——————0023025282612000
General and administrative787778911121821263540525255
Operating income9−10−25−12−136−22−19−26−48−37−55−100−75−146−243−317
Interest expense——————0016753100—
Income before tax9−9−25−12−136−22−18−53−57−45−58−102−71−131−232—
Income tax0−0−0−0−00−00000000000
Net income9−9−25−12−136−22−18−53−57−45−58−102−71−131−232−307
Diluted EPS$4.60−$0.44−$11.90−$5.20−$4.90$2.10−$0.68−$5.20−$1.15−$5.44−$3.54−$2.03−$2.74−$1.82−$2.32−$3.17−$3.76
Diluted shares (average)2m2m2m2m3m3m3m4m5m10m13m29m37m39m56m73m81m
EBITDA9−10−25−12−137−22−18−26−48−37−55−99−75−144−241−314

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EYPT vs TXMDCPHI vs EYPTEYPT vs NTRB

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Eyepoint, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Eyepoint, Inc.